Abstract:Malignant melanoma is the most aggressive form of skin cancer. Standard treatment options include surgery, radiation therapy, systemic chemotherapy, targeted therapy, and immunotherapy. Combining these modalities often yields better responses. Surgery is suitable for localized cases, sometimes involving lymph node dissection and biopsy, to assess the spread of the disease. Radiation therapy may be sometimes used as a standalone treatment or following surgical excision. Systemic chemotherapy, while having low response rates, is utilized as part of combination treatments or when other methods fail. The development of resistance to systemic chemotherapies and associated side effects have prompted further research and clinical trials for novel approaches. In the case of advanced-stage melanoma, a comprehensive approach may be necessary, incorporating targeted therapies and immunotherapies that demonstrate significant antitumor activity. Targeted therapies, including inhibitors targeting BRAF, MEK, c-KIT, and NRAS, are designed to block the specific molecules responsible for tumor growth. These therapies show promise, particularly in patients with corresponding mutations. Combination therapy, including BRAF and MEK inhibitors, has been evidenced to improve progression-free survival; however, concerns about resistance and cutaneous toxicities highlight the need for close monitoring. Immunotherapies, leveraging tumor-infiltrating lymphocytes and CAR T cells, enhance immune responses. Lifileucel, an FDA-approved tumor-infiltrating lymphocyte therapy, has demonstrated improved response rates in advanced-stage melanoma. Ongoing trials continue to explore the efficacy of CAR T-cell therapy for advanced melanoma. Checkpoint inhibitors targeting CTLA-4 and PD-1 have enhanced outcomes. Emerging IL-2 therapies boost dendritic cells, enhancing anticancer immunity. Oncolytic virus therapy, approved for advanced melanoma, augments treatment efficacy in combination approaches. While immunotherapy has significantly advanced melanoma treatment, its success varies, prompting research into new drugs and factors influencing outcomes. This review provides insights into current melanoma treatments and recent therapeutic advances.

Cutaneous melanoma and the immunotherapy revolution (Review)

Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy

Cutaneous melanoma: From pathogenesis to therapy (Review)

Immunotherapy of Melanoma: a Critical Review of Current Concepts and Future Strategies

Immunotherapy of melanoma: a critical review of current concepts and future strategies.

Immunotherapy for Skin Cancer

Combining Immunotherapy with Oncogene-Targeted Therapy: A New Road for Melanoma Treatment

The treatment of advanced melanoma: Current approaches and new challenges

A Review of Current and Pipeline Drugs for Treatment of Melanoma

From Conventional Therapies to Immunotherapy: Melanoma Treatment in Review

Interaction of Molecular Alterations with Immune Response in Melanoma

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions

Advances in the discovery and development of melanoma drug therapies

Immunotherapy of Human Melanoma: Past, Present, Future

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment

Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials

Advances in treatment of melanoma with immunotherapy

Therapeutic options in cutaneous melanoma: latest developments

Advances in Melanoma: From Genetic Insights to Therapeutic Innovations

Adoptive Cell Transfer and Vaccines in Melanoma: The Horizon Comes Into View

Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update